Objective  To analyze the hotspots and development trends of the economic burden of acute ischemic stroke, and to provide a reference for researchers in China to conduct related studies.

Methods  Web of Science Core Collection database was searched to collect relevant reviews or articles on the economic burden of acute ischemic stroke from January 1994 to December 2023. CiteSpace 6.1.R6 software was used to visualize the authors, countries/regions, research institutions, keywords, and co-cited references.

Results  A total of 1,162 articles were include. The United States was the country with highest number of publications and centrality. China ranked the second in publication volume, but its centrality ranking was relatively low. Among the top 10 institutions in terms of publication volume, 6 were from the United States, and Capital Medical University was the only Chinese institution listed. The cost-effectiveness analysis of treatment plans, scientific management method, and the cost-effectiveness analysis of treatment plans were the main research topics. The past three years had focused primarily on the cost-effectiveness analysis of treatment plans.

Conclusion  The study of the economic burden of acute ischemic stroke has advanced rapidly in recent years, but there is still a significant gap between China and developed western countries such as the United States. Chinese researchers should research current hotspots, while also addressing the early foundation studies of these hotspots, providing beneficial conditions for conducting hotspot research.

1.虞莉莎, 刘新靓, 宋康, 等. 中国脑卒中环境危险因素的系统评价[J]. 医学新知, 2023, 33(3): 173-208. [Yu LS, Liu XL, Song K, et al. Environmental risk factors for stroke in China: a systematic review[J]. Yixue Xinzhi Zazhi, 2023, 33(3): 173-208.] DOI: 10.12173/j.issn.1004-5511.202209017.

2.Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1.

3.王陇德, 彭斌, 张鸿祺, 等. 《中国脑卒中防治报告2020》概要[J]. 中国脑血管病杂志, 2022, 19(2): 136-144. [Wang LD, Peng B, Zhang HQ, et al. Brief report on Stroke Prevention and Treatment in China, 2020[J]. Chinese Journal of Cerebrovascular Diseases, 2022, 19(2): 136-144.] DOI: 10.3969/j.issn.1672-5921.2022.02.011.

4.Kaur P, Kwatra G, Kaur R, et al. Cost of stroke in low and middle income countries: a systematic review[J]. Int J Stroke, 2014, 9(6): 678-682. DOI: 10.1111/ijs.12322.

5.Roldán-Valadez E, Salazar-Ruiz SY, Ibarra-Contreras R, et al. Current concepts on bibliometrics: a brief review about impact factor, Eigenfactor score, CiteScore, SCImago Journal Rank, Source-Normalised Impact per Paper, H-index, and alternative metrics[J]. Ir J Med Sci, 2019, 188(3): 939-951. DOI: 10.1007/s11845-018-1936-5.

6.Synnestvedt MB, Chen C, Holmes JH. CiteSpace Ⅱ: visualization and knowledge discovery in bibliographic databases[J]. AMIA Annu Symp Proc, 2005, 2005: 724-728. DOI: 10.1002/asi.20317.

7.马进原, 郑心怡, 张翠珍, 等. 基于Web of Science的免疫抑制药基因组学研究的文献计量分析[J]. 药物流行病学杂志, 2023, 32(4): 391-403. [Ma JY, Zheng XY, Zhang CZ, et al. Bibliometric analysis of the research of immunosuppressive pharmacogenomics based on Web of Science database[J]. Chinese Journal of Pharmacoepidemiology, 2023, 32(4): 391-403.] DOI: 10.19960/j.issn.1005-0698.202304005.

8.李杰, 陈超美, 主编. CiteSpace科技文本挖掘及可视化[M]. 北京: 首都经济贸易大学出版社, 2022: 1-281.

9.Chen CM. Science mapping: a systematic review of the literature[J]. J Data Inform Sci, 2017, 2(2): 1-40. DOI: 10.1515/jdis-2017-0006.

10.Shireman TI, Wang K, Saver JL, et al. Cost-effectiveness of solitaire stent retriever thrombectomy for acute ischemic stroke: results from the SWIFT-PRIME trial (solitaire with the intention for thrombectomy as primary endovascular treatment for acute ischemic stroke)[J]. Stroke, 2017, 48(2): 379-387. DOI: 10.1161/STROKEAHA.116.014735.

11.Pineo G, Lin J, Stern L, et al. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial[J]. J Hosp Med, 2012, 7(3): 176-182. DOI: 10.1002/jhm.968.

12.Sevick LK, Ghali S, Hill MD, et al. Systematic review of the cost and cost-effectiveness of rapid endovascular therapy for acute ischemic stroke[J]. Stroke, 2017, 48(9): 2519-2526. DOI: 10.1161/STROKEAHA.117.017199.

13.Krueger H, Lindsay P, Cote R, et al. Cost avoidance associated with optimal stroke care in Canada[J]. Stroke, 2012, 43(8): 2198-2206. DOI: 10.1161/STROKEAHA.111.646091.

14.Kunz WG, Hunink MG, Almekhlafi M, et al. Public health and cost consequences of time delays to thrombectomy for acute ischemic stroke[J]. Neurology, 2020, 95(18): e2465-e2475. DOI: 10.1212/WNL.0000000000010867.

15.Simpson KN, Simpson AN, Mauldin PD, et al. Drivers of costs associated with reperfusion therapy in acute stroke: the interventional management of stroke Ⅲ trial[J]. Stroke, 2014, 45(6): 1791-1798. DOI: 10.1161/STROKEAHA.113.003874.

16.Lobotesis K, Veltkamp R, Carpenter IH, et al. Cost-effectiveness of stent-retriever thrombectomy in combination with Ⅳ t-PA compared with IV t-PA alone for acute ischemic stroke in the UK[J]. J Med Econ, 2016, 19(8): 785-794. DOI: 10.1080/13696998.2016.1174868.

17.Brinjikji W, Rabinstein AA, Cloft HJ. Hospitalization costs for acute ischemic stroke patients treated with intravenous thrombolysis in the United States are substantially higher than Medicare payments[J]. Stroke, 2012, 43(4): 1131-1133. DOI: 10.1161/STROKEAHA.111.636142.

18.Kleindorfer D, Broderick J, Demaerschalk B, et al. Cost of alteplase has more than doubled over the past decade[J]. Stroke, 2017, 48(7): 2000-2002. DOI: 10.1161/strokeaha.116.015822.

19.Pan Y, Cai X, Huo X, et al. Cost-effectiveness of mechanical thrombectomy within 6 hours of acute ischaemic stroke in China[J]. BMJ Open, 2018, 8(2): e018951. DOI: 10.1136/bmjopen-2017-018951.

20.Pan Y, Chen Q, Zhao X, et al. TIMS-CHINA Investigators. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China[J]. PLoS One, 2014, 9(10): e110525. DOI: 10.1371/journal.pone.0110525.

21.Strilciuc S, Grad DA, Radu C, et al. The economic burden of stroke: a systematic review of cost of illness studies[J]. J Med Life, 2021, 14(5): 606-619. DOI: 10.25122/jml-2021-0361.

22.Katzenellenbogen JM, Vos T, Somerford P, et al. Burden of stroke in indigenous Western Australians: a study using data linkage[J]. Stroke, 2011, 42(6): 1515-1521. DOI: 10.1161/STROKEAHA.110.601799.

23.Kang HY, Lim SJ, Suh HS, et al. Estimating the lifetime economic burden of stroke according to the age of onset in South Korea: a cost of illness study[J]. BMC Public Health, 2011, 11: 646. DOI: 10.1186/1471-2458-11-646.

24.胡善联, 龚向光. 中国缺血性脑卒中的疾病经济负担[J]. 中国卫生经济, 2023, (12): 18-20. [Hu SL, Gong XG. Economic burden of ischemic stroke in China[J]. Chinese Health Economy, 2023, (12): 18-20.] DOI: 10.3969/j.issn.1003-0743.2003.12.008.

25.Tung CE, Win SS, Lansberg MG. Cost-effectiveness of tissue-type plasminogen activator in the 3 - to 4.5 - hour time window for acute ischemic stroke[J]. Stroke, 2011, 42(8): 2257-2262. DOI: 10.1161/STROKEAHA.111.615682.

26.Chen J, Liang X, Tong X, et al. Economic evaluation of intravenous alteplase for stroke with the time of onset between 4.5 and 9 hours[J]. J Neurointerv Surg, 2023, 15(1): 46-51. DOI: 10.1136/neurintsurg-2021-018420.

27.Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke[J]. N Engl J Med, 2015, 372(1): 11-20. DOI: 10.1056/NEJMoa1411587.

28.Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke[J]. N Engl J Med, 2015, 372(24): 2285-2295. DOI: 10.1056/NEJMoa1415061.

29.Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection[J]. N Engl J Med, 2015, 372(11): 1009-1018. DOI: 10.1056/NEJMoa1414792.

30.Menon BK, d'Esterre CD, Qazi EM, et al. Multiphase CT angiography: a new tool for the imaging triage of patients with acute ischemic stroke[J]. Radiology, 2015, 275(2): 510-520. DOI: 10.1148/radiol.15142256.

31.Jovin Tudor G, Chamorro Angel, Cobo Erik, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke[J]. N Engl J Med, 2015, 372(24): 2296-306. DOI: 10.1056/NEJMoa1503780.

32.Aronsson M, Persson J, Blomstrand C, et al. Cost-effectiveness of endovascular thrombectomy in patients with acute ischemic stroke[J]. Neurology, 2016, 86(11): 1053-1059. DOI: 10.1212/WNL.0000000000002439.

33.中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9): 666-682. [Chinese Society of Neurology, Cerebrovascular Disease Group of Chinese Society of Neurology. Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018[J]. Chinese Journal of Neurology, 2018, 51(9): 666-682.] DOI: 10.3760/cma.j.issn.1006-7876.2018. 09.004.

34.Bivard A, Zhao H, Churilov L, et al. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial[J]. Lancet Neurol, 2022, 21(6): 520-527. DOI: 10.1016/S1474-4422(22)00171-5.

35.缪中荣, 霍晓川. 未来已来: 急性缺血性卒中血管内治疗中国现状[J]. 中国卒中杂志, 2021, 16(11): 1085-1090. DOI: 10.3969/j.issn.1673-5765.2023.06.010.